CN115501182A - 一种牛蒡苷元液体纳米制剂及其制备方法 - Google Patents
一种牛蒡苷元液体纳米制剂及其制备方法 Download PDFInfo
- Publication number
- CN115501182A CN115501182A CN202211159865.3A CN202211159865A CN115501182A CN 115501182 A CN115501182 A CN 115501182A CN 202211159865 A CN202211159865 A CN 202211159865A CN 115501182 A CN115501182 A CN 115501182A
- Authority
- CN
- China
- Prior art keywords
- arctigenin
- oil
- liquid
- emulsifier
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 title claims abstract description 102
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 title claims abstract description 102
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 title claims abstract description 102
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 title claims abstract description 102
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 title claims abstract description 102
- 239000007788 liquid Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000002245 particle Substances 0.000 claims abstract description 16
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 7
- 239000003921 oil Substances 0.000 claims description 44
- 235000019198 oils Nutrition 0.000 claims description 44
- 239000003995 emulsifying agent Substances 0.000 claims description 27
- 239000010636 coriander oil Substances 0.000 claims description 20
- 235000011803 sesame oil Nutrition 0.000 claims description 18
- 239000008159 sesame oil Substances 0.000 claims description 18
- 239000010630 cinnamon oil Substances 0.000 claims description 17
- 239000007957 coemulsifier Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 10
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 9
- 239000004359 castor oil Substances 0.000 claims description 9
- 235000019438 castor oil Nutrition 0.000 claims description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 9
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 9
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 229960004063 propylene glycol Drugs 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000035605 chemotaxis Effects 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 239000012071 phase Substances 0.000 description 41
- 241000208843 Arctium Species 0.000 description 4
- 235000003130 Arctium lappa Nutrition 0.000 description 4
- 235000008078 Arctium minus Nutrition 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000011837 pasties Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 3
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了一种牛蒡苷元液体纳米制剂及其制备方法,涉及药物制剂技术领域。本发明将牛蒡苷元制成液体纳米制剂,液滴粒径在纳米级别分布,比表面积显著增大,具有吸收快,生物利用度高的优点。同时,进入机体内的纳米制剂可被游走的白细胞捕获,并经趋化作用将药物携带至炎性病灶,从而使牛蒡苷元药物具备了靶向投药的特征,治疗更有针对性。此外,本发明将牛蒡苷元溶解在油相中,再将该油相通过乳化方式溶解于水中,使得牛蒡苷元也溶解于水,提高了牛蒡苷元在水中的溶解度,一方面提高了生物利用度,另一方面可将其制备成注射液、口服液等剂型,相比将其制备成片剂、胶囊等吞咽困难的固体剂型,使用方法上更具优势。
Description
技术领域
本发明涉及药物制剂技术领域,尤其涉及一种牛蒡苷元液体纳米制剂及其制备方法。
背景技术
牛蒡苷元是牛蒡的活性成分,外观为结晶性粉末,研究表明其具有较好的抗炎、抗免疫调节、抗病毒、抗肿瘤活性,在医药行业有着广泛的应用前景,但由于该药水溶性较差,临床使用后在体内靶向性不强,导致药物实际生物利用度并不高,进入体内后真正在炎性区域分布的药量较少,药效无法充分发挥。
发明内容
本发明的目的在于提供一种牛蒡苷元纳米制剂及其制备方法,提高了牛蒡苷元在水中的溶解度和生物利用度。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种牛蒡苷元液体纳米制剂,包括水相、油相、乳化剂和助乳化剂;所述牛蒡苷元溶解在所述油相中;所述油相分散于所述水相中呈水包油结构;所述牛蒡苷元纳米制剂的液滴粒径小于100nm。
优选的,所述油相包括肉桂油、芫荽油和麻油。
优选的,所述油相中肉桂油、芫荽油和麻油的质量比为(0.5~2.5):(1.0~6.0):(2.0~4.0)。
优选的,总量以100g计,包括牛蒡苷元0.1~3.0g、肉桂油0.5~2.5g、芫荽油1.0~6.0g、麻油2.0~4.0g、乳化剂21~35g、助乳化剂2.0~5.0g,余量为水。
优选的,总量以100g计,包括牛蒡苷元0.5~2.5g、肉桂油1.0~2.0g、芫荽油2.0~5.0g、麻油2.5~3.5g、乳化剂23~33g、助乳化剂2.5~4.5g,余量为水。
优选的,总量以100g计,包括牛蒡苷元1.5g、肉桂油1.5g、芫荽油3.5g、麻油3.0g、乳化剂28.0g、助乳化剂3.5g,余量为水。
优选的,所述乳化剂包括吐温-20和聚氧乙烯醚40氢化蓖麻油;所述吐温-20和聚氧乙烯醚40氢化蓖麻油的质量比为(15~25):(6~10)。
优选的,所述助乳化剂包括1,2-丙二醇。
优选的,所述牛蒡苷元纳米制剂的液滴粒径小于50nm。
本发明提供了上述方案所述牛蒡苷元液体纳米制剂的制备方法,包括以下步骤:
将牛蒡苷元溶解到油相中,得到溶解牛蒡苷元的油相;
将所述溶解牛蒡苷元的油相与乳化剂和助乳化剂混合,在搅拌和超声条件下,向所得混合体系中加入水,进行乳化,得到所述牛蒡苷元液体纳米制剂;所述超声的频率为40kHz。
本发明提供了一种牛蒡苷元液体纳米制剂,包括水相、油相、乳化剂和助乳化剂;所述牛蒡苷元溶解在所述油相中;所述油相分散于所述水相中呈水包油结构;所述牛蒡苷元纳米制剂的液滴粒径小于100nm。
本发明将牛蒡苷元制成液体纳米制剂,液滴粒径在纳米级别分布,比表面积显著增大,具有吸收快,生物利用度高的优点。同时,进入机体内的纳米制剂可被游走的白细胞捕获,并经趋化作用将药物携带至炎性病灶,从而使牛蒡苷元药物具备了靶向投药的特征,治疗更有针对性。
此外,本发明将牛蒡苷元溶解在油相中,再将该油相通过乳化方式溶解于水中,使得牛蒡苷元也溶解于水,提高了牛蒡苷元在水中的溶解度,一方面提高了生物利用度,另一方面可将其制备成注射液、口服液等剂型,相比将其制备成片剂、胶囊等吞咽困难的固体剂型,使用方法上更具优势。
进一步的,本发明选择肉桂油、芫荽油和麻油作为牛蒡苷元的载体,一方面这三种油组成的混合油相能确保牛蒡苷元制备成纳米制剂时有较高的载药量和符合要求的稳定性,另一方面利用了肉桂油的祛风湿,温健脾胃之功效,芫荽油的健胃、祛风、去痰的功效,麻油的润燥、解毒、止痛、消肿之功效,和牛蒡苷元组成复方制剂,显著提升疾病治疗效果。
附图说明
图1为实施例1制备的牛蒡苷元液体纳米制剂的粒度分布图;
图2为实施例1制备的牛蒡苷元液体纳米制剂的电子显微镜图片。
具体实施方式
本发明提供了一种牛蒡苷元液体纳米制剂,包括水相、油相、乳化剂和助乳化剂;所述牛蒡苷元溶解在所述油相中;所述油相分散于所述水相中呈水包油结构;所述牛蒡苷元纳米制剂的液滴粒径小于100nm。
在本发明中,所述水相优选为去离子水。
在本发明中,所述油相优选包括肉桂油、芫荽油和麻油;所述肉桂油、芫荽油和麻油的质量比优选为(0.5~2.5):(1.0~6.0):(2.0~4.0),更优选为(1.0~2.0):(2.0~5.0):(2.5~3.5),进一步优选为1.5:3.5:3。
在本发明中,所述乳化剂优选包括吐温-20和聚氧乙烯醚40氢化蓖麻油;所述吐温-20和聚氧乙烯醚40氢化蓖麻油的质量比优选为(15~25):(6~10),更优选为(16~24):(7~9),进一步优选为20:8。在本发明中,所述乳化剂主要起到将油相乳化后使牛蒡苷元和油相共同溶解于水相的作用,同时形成纳米级别的液滴。
在本发明中,所述助乳化剂优选包括1,2-丙二醇。所述助乳化剂能够增强液体纳米制剂的稳定性,防止后期存放过程中出现破乳。
在本发明中,总量以100g计,本发明所述牛蒡苷元液体纳米制剂优选包括牛蒡苷元0.1~3.0g、肉桂油0.5~2.5g、芫荽油1.0~6.0g、麻油2.0~4.0g、乳化剂21~35g、助乳化剂2.0~5.0g,余量为水;更优选包括牛蒡苷元0.5~2.5g、肉桂油1.0~2.0g、芫荽油2.0~5.0g、麻油2.5~3.5g、乳化剂23~33g、助乳化剂2.5~4.5g,余量为水;进一步优选包括牛蒡苷元1.5g、肉桂油1.5g、芫荽油3.5g、麻油3.0g、乳化剂28.0g、助乳化剂3.5g,余量为水。
在本发明中,所述牛蒡苷元纳米制剂的液滴粒径优选小于50nm,更优选小于40nm,进一步优选为1~35nm。
本发明提供了上述方案所述牛蒡苷元液体纳米制剂的制备方法,包括以下步骤:
将牛蒡苷元溶解到油相中,得到溶解牛蒡苷元的油相;
将所述溶解牛蒡苷元的油相与乳化剂和助乳化剂混合,在搅拌和超声条件下,向所得混合体系中加入水,进行乳化,得到所述牛蒡苷元液体纳米制剂;所述超声的频率为40kHz。
本发明将牛蒡苷元溶解到油相中,得到溶解牛蒡苷元的油相。在本发明中,所述油相优选由肉桂油、芫荽油和麻油混合得到。本发明对所述溶解的过程没有特殊要求。
得到溶解牛蒡苷元的油相后,本发明将所述溶解牛蒡苷元的油相与乳化剂和助乳化剂混合,在搅拌和超声条件下,向所得混合体系中加入水,进行乳化,得到所述牛蒡苷元液体纳米制剂;所述超声的频率为40kHz。
本发明对所述溶解牛蒡苷元的油相与乳化剂和助乳化剂混合的过程没有特殊要求,本领域熟知的能够混合均匀的方式均可。
本发明对所述搅拌的速率没有特殊要求,采用本领域熟知的搅拌速率即可。本发明控制超声的频率为40kHz,可以确保形成纳米级别的粒径,且乳液稳定。
本发明对所述搅拌和超声的时间没有特殊要求,待体系由液态转变为膏状半固态,之后再转变为液态,即可停止,然后冷却至室温,得到所述牛蒡苷元液体纳米制剂。
下面结合实施例对本发明提供的牛蒡苷元液体纳米制剂及其制备方法进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
将1.5g肉桂油、3.5g芫荽油和3.0g麻油混合,加入1.5g牛蒡苷元搅拌溶解,得到溶解牛蒡苷元的油相;
将20.0g吐温-20和8.0g聚氧乙烯醚40氢化蓖麻油混合均匀,再加入3.5g1,2-丙二醇混合,之后将混合物置于溶解牛蒡苷元的油相中,搅拌均匀后于40kHz的超声条件下,边搅拌边加入59.0g去离子水,体系由液态转变为膏状半固态,之后再转变为液态,冷却至室温,二次摇匀后得到牛蒡苷元液体纳米制剂。
经激光粒度分析仪检测和电子显微镜观察,结果如图1和图2所示,本发明牛蒡苷元液体纳米制剂粒径分布在5~28nm之间,整体形态呈球形或类球形。
将牛蒡苷元原料加入室温下纯水中,溶解度小于0.05%,本发明实施例1牛蒡苷元在水中的溶解度达到了1.5%(即100g本发明牛蒡苷元液体纳米制剂中含1.5g牛蒡苷元,能够使得1.5g牛蒡苷元溶解到水中),且能在水中无限稀释。水溶性提高后,无论是吸收进入血液还是组织液,因血液和组织液是一个由水为主成分的体系,故生物利用度会显著提高。
实施例2
将0.5g肉桂油、1.0g芫荽油和2.0g麻油混合,加入0.1g牛蒡苷元搅拌溶解,得到溶解牛蒡苷元的油相;
将15.0g吐温-20和6.0g聚氧乙烯醚40氢化蓖麻油混合均匀,再加入2.0g1,2-丙二醇混合,之后将混合物置于溶解牛蒡苷元的油相中,搅拌均匀后于40kHz的超声条件下,边搅拌边加入73.4g去离子水,体系由液态转变为膏状半固态,之后再转变为液态,冷却至室温,二次摇匀后得到牛蒡苷元纳米制剂。经激光粒度分析仪检测,显示粒径分布在3~30nm之间。
实施例3
将2.5g肉桂油、6.0g芫荽油和4.0g麻油混合,加入3.0g牛蒡苷元搅拌溶解,得到溶解牛蒡苷元的油相;
将25.0g吐温-20和10.0g聚氧乙烯醚(40)氢化蓖麻油混合均匀,再加入5.0g1,2-丙二醇混合,之后将混合物置于溶解牛蒡苷元的油相中,搅拌均匀后于40kHz的超声条件下,边搅拌边加入44.5g去离子水,体系由液态转变为膏状半固态,之后再转变为液态,冷却至室温,二次摇匀后得到牛蒡苷元液体纳米制剂。经激光粒度分析仪检测,显示粒径分布在3~30nm之间
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种牛蒡苷元液体纳米制剂,其特征在于,包括水相、油相、乳化剂和助乳化剂;所述牛蒡苷元溶解在所述油相中;所述油相分散于所述水相中呈水包油结构;所述牛蒡苷元纳米制剂的液滴粒径小于100nm。
2.根据权利要求1所述的牛蒡苷元液体纳米制剂,其特征在于,所述油相包括肉桂油、芫荽油和麻油。
3.根据权利要求2所述的牛蒡苷元液体纳米制剂,其特征在于,所述油相中肉桂油、芫荽油和麻油的质量比为(0.5~2.5):(1.0~6.0):(2.0~4.0)。
4.根据权利要求3所述的牛蒡苷元液体纳米制剂,其特征在于,总量以100g计,包括牛蒡苷元0.1~3.0g、肉桂油0.5~2.5g、芫荽油1.0~6.0g、麻油2.0~4.0g、乳化剂21~35g、助乳化剂2.0~5.0g,余量为水。
5.根据权利要求4所述的牛蒡苷元液体纳米制剂,其特征在于,总量以100g计,包括牛蒡苷元0.5~2.5g、肉桂油1.0~2.0g、芫荽油2.0~5.0g、麻油2.5~3.5g、乳化剂23~33g、助乳化剂2.5~4.5g,余量为水。
6.根据权利要求5所述的牛蒡苷元液体纳米制剂,其特征在于,总量以100g计,包括牛蒡苷元1.5g、肉桂油1.5g、芫荽油3.5g、麻油3.0g、乳化剂28.0g、助乳化剂3.5g,余量为水。
7.根据权利要求1~6任一项所述的牛蒡苷元液体纳米制剂,其特征在于,所述乳化剂包括吐温-20和聚氧乙烯醚40氢化蓖麻油;所述吐温-20和聚氧乙烯醚40氢化蓖麻油的质量比为(15~25):(6~10)。
8.根据权利要求1~6任一项所述的牛蒡苷元液体纳米制剂,其特征在于,所述助乳化剂包括1,2-丙二醇。
9.根据权利要求1~6任一项所述的牛蒡苷元液体纳米制剂,其特征在于,所述牛蒡苷元纳米制剂的液滴粒径小于50nm。
10.权利要求1~9任一项所述牛蒡苷元液体纳米制剂的制备方法,其特征在于,包括以下步骤:
将牛蒡苷元溶解到油相中,得到溶解牛蒡苷元的油相;
将所述溶解牛蒡苷元的油相与乳化剂和助乳化剂混合,在搅拌和超声条件下,向所得混合体系中加入水,进行乳化,得到所述牛蒡苷元液体纳米制剂;所述超声的频率为40kHz。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211159865.3A CN115501182A (zh) | 2022-09-22 | 2022-09-22 | 一种牛蒡苷元液体纳米制剂及其制备方法 |
US17/988,031 US20240100015A1 (en) | 2022-09-22 | 2022-11-16 | Arctigenin liquid nano-preparation and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211159865.3A CN115501182A (zh) | 2022-09-22 | 2022-09-22 | 一种牛蒡苷元液体纳米制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115501182A true CN115501182A (zh) | 2022-12-23 |
Family
ID=84506881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211159865.3A Pending CN115501182A (zh) | 2022-09-22 | 2022-09-22 | 一种牛蒡苷元液体纳米制剂及其制备方法 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20240100015A1 (zh) |
CN (1) | CN115501182A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100029114A (ko) * | 2010-02-24 | 2010-03-15 | 주식회사 코리아나화장품 | 악티게닌 또는 악티게닌 유도체를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물 |
CN102210653A (zh) * | 2010-04-03 | 2011-10-12 | 鲁南制药集团股份有限公司 | 牛蒡苷元的微乳制剂 |
CN102342928A (zh) * | 2010-07-23 | 2012-02-08 | 山东新时代药业有限公司 | 牛蒡苷元的医药用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140056828A1 (en) * | 2012-08-21 | 2014-02-27 | Indiran Pather | Novel formulations and uses for curcuma extracts |
-
2022
- 2022-09-22 CN CN202211159865.3A patent/CN115501182A/zh active Pending
- 2022-11-16 US US17/988,031 patent/US20240100015A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100029114A (ko) * | 2010-02-24 | 2010-03-15 | 주식회사 코리아나화장품 | 악티게닌 또는 악티게닌 유도체를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물 |
CN102210653A (zh) * | 2010-04-03 | 2011-10-12 | 鲁南制药集团股份有限公司 | 牛蒡苷元的微乳制剂 |
CN102342928A (zh) * | 2010-07-23 | 2012-02-08 | 山东新时代药业有限公司 | 牛蒡苷元的医药用途 |
Also Published As
Publication number | Publication date |
---|---|
US20240100015A1 (en) | 2024-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69634246T2 (de) | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit | |
US4719239A (en) | Pharmaceutical multicomponent systems and method of preparing same | |
US6623761B2 (en) | Method of making nanoparticles of substantially water insoluble materials | |
JP3391961B2 (ja) | サイクロスポリン含有軟質カプセル剤組成物 | |
DE60018372T2 (de) | Oralzusammensetzung als mikroemulsion von silybin | |
US20040147578A1 (en) | Use of lipoaminoacids as absorption promoters in a pharmaceutical composition | |
JP5134547B2 (ja) | アデノシルコバラミン含有の皮膚疾患改善用外用剤組成物 | |
CA2458448A1 (en) | Spontaneous emulsions containing cyclosporine | |
AU2010256130A1 (en) | Preparation method of drug loaded emulsion | |
CN1748777A (zh) | 一种中药挥发油自微乳化纳米组合物及制备方法 | |
RU2362545C2 (ru) | Двухжидкостные пены, стабильная дисперсия на их основе и способ ее получения | |
JPH01151526A (ja) | 薬理活性化合物および医薬賦形剤用可溶化剤としての水溶性モノエステル類 | |
CN101703468A (zh) | 维生素e油纳米乳制剂与制备方法 | |
EP0945136B1 (de) | Topisches Arzneimittel mit einem Gehalt an Ciclosporin | |
WO2011103806A1 (zh) | 榄香烯口服微乳 | |
WO2008065514A2 (en) | Pharmaceutical compositions containing anhydrous calcipotriene | |
US20080171687A1 (en) | Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs | |
WO2016182926A1 (en) | Preparation of nanoemulsions | |
US20130259915A1 (en) | Method for the treatment of skin | |
CN101829055A (zh) | 一种紫杉醇纳米自微乳及其制备方法 | |
CN115501182A (zh) | 一种牛蒡苷元液体纳米制剂及其制备方法 | |
EP1249231A1 (de) | Pharmazeutische Formulierungen enthaltend entzündungshemmende Wirkstoffe und deren Verwendung | |
CN101199479A (zh) | 一种药用亚微乳剂及其制备方法 | |
CN107875038B (zh) | 一种橄榄油微乳制剂及其作为美白防晒剂的应用 | |
CN112870161B (zh) | 一种雪松醇纳米乳及其优化制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |